Sotrovimab (VIR-7831/GSK4182136) Antibody, Monoclonal | 21-878

Sotrovimab (VIR-7831/GSK4182136) Antibody, Monoclonal | 21-878 | Gentaur UK, US & Europe Distribution

Product Type: Primary Antibodies

Category: Primary Antibodies, Monoclonal Antibodies

Research Area: Drug Analogues

Type: Monoclonal

Host Species: N/A

Reactivity Species: N/A

Homology: N/A

Immunology: Humanized / Spike glycoprotein [SARS-CoV-2]

Tested Application: N/A

Application Note: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Predicted Molecular Weight: N/A

Isoform: N/A

Purification: >95%

Clonality: Recombinant Monoclonal

Clone: N/A

Isotype: Human IgG

Conjugate: Unconjugated

Physical State: N/A

Buffer: PBS buffer pH 7.5

Concentration: N/A

Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at +4°C short term (1-2 weeks) . Store at -20 °C 12 months. Store at -80°C long term.

Additional Names: VIR-7831, GSK4182136, spike glycoprotein

Protein Accession: P0DTC2

User Note: For research use only .

Background: VIR-7831 (GSK4182136) is a fully human anti-SARS-CoV-2 monoclonal antibody selected based on its potential to neutralize the virus in vitro, kill infected cells, provide a high barrier to resistance, and achieve high concentrations in the lungs (one of the major sites of infection) . VIR-7831 is a dual-action monoclonal antibody that was selected for clinical development based on its potential to both block viral entry into healthy cells and clear infected cells, as well as its potential to provide a high barrier to resistance. Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS) . The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Loading Controls: N/A

Source: XtenCHO

Purity: >95%

CAS: N/A

Shipping Condition: N/A